HEPA - Hepion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0050
+0.0450 (+1.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.9600
Open2.9900
Bid0.0000 x 2900
Ask0.0000 x 2200
Day's Range2.9510 - 3.0600
52 Week Range2.0000 - 4.4500
Volume77,802
Avg. Volume286,412
Market Cap10.378M
Beta (3Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)-50.5790
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference

    EDISON, N.J., Sept. 04, 2019 -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.

  • GlobeNewswire

    Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

    Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that it has received notification from the Nasdaq Hearings Panel (the “Panel”) that it has regained compliance with Nasdaq’s minimum shareholders’ equity rule, and is in compliance with other applicable requirements as set forth in the Panel’s decision dated May 3, 2019 and required for listing on The Nasdaq Stock Market. The Company's shares will continue to be traded on The Nasdaq Stock Market under the symbol HEPA.

  • GlobeNewswire

    Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431

    Designed to assess safety, tolerability and pharmacokinetics of CRV431, this study is the third and final stage of CRV431's streamlined early clinical program, which was agreed upon with the U.S. Food and Drug Administration (“FDA”). “Having established safety and tolerability of CRV431 alone, as well as when co-dosed with TDF, this trial will monitor safety, tolerability and pharmacokinetics of CRV431 when administered repeatedly for 28 days in virally-suppressed HBV patients,” stated Dr. Foster, Hepion’s CEO.

  • GlobeNewswire

    Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board

    Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that Dr. Stephen Harrison has joined its Scientific Advisory Board. “We are honored to have Dr. Harrison, an internationally recognized hepatologist (liver disease expert), join our Scientific Advisory Board,” commented Dr. Carol Brosgart, Clinical Professor of Medicine in the Divisions of Global Health Sciences, Biostatistics and Epidemiology in the Department of Medicine at the University of California, San Francisco and Chair of the Company’s Scientific Advisory Board.

  • GlobeNewswire

    Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta

    Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced it entered into a research partnership with Applied Pharmaceutical Innovation (“API”), an independent institute that launched out of the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta (“FPPS”) in Edmonton, Canada that is focused on empowering the growth and development of the Canadian pharmaceutical industry in collaboration with post-secondary centers of excellence.